These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 11009042)

  • 1. The role of aminosalicylates at the beginning of the new millennium in the treatment of chronic inflammatory bowel disease.
    Klotz U
    Eur J Clin Pharmacol; 2000 Aug; 56(5):353-62. PubMed ID: 11009042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug insight: aminosalicylates for the treatment of IBD.
    Nielsen OH; Munck LK
    Nat Clin Pract Gastroenterol Hepatol; 2007 Mar; 4(3):160-70. PubMed ID: 17339853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease.
    Hanauer SB; Stathopoulos G
    Drug Saf; 1991; 6(3):192-219. PubMed ID: 1676590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review article: new developments in the use of 5-aminosalicylic acid in patients with inflammatory bowel disease.
    Thomson AB
    Aliment Pharmacol Ther; 1991 Oct; 5(5):449-70. PubMed ID: 1793778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How important is onset of action in ulcerative colitis therapy?
    Masson S; Nylander D; Mansfield JC
    Drugs; 2005; 65(15):2069-83. PubMed ID: 16225364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review article: aminosalicylates in inflammatory bowel disease.
    Hanauer SB
    Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 4():60-5. PubMed ID: 15352896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolerability of aminosalicylates in inflammatory bowel disease.
    Ishaq S; Green JR
    BioDrugs; 2001; 15(5):339-49. PubMed ID: 11437696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease.
    Brogden RN; Sorkin EM
    Drugs; 1989 Oct; 38(4):500-23. PubMed ID: 2684592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Controversies with aminosalicylates in inflammatory bowel disease.
    Lim WC; Hanauer SB
    Rev Gastroenterol Disord; 2004; 4(3):104-17. PubMed ID: 15359211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapeutic efficacy of 5-ASA molecules in idiopathic intestinal inflammatory diseases: critical review].
    Van Gossum A
    Acta Gastroenterol Belg; 1992; 55(5-6):462-71. PubMed ID: 1363167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [5-aminosalicylic acid in the treatment of ulcerative colitis and Crohn's disease].
    Moum B
    Tidsskr Nor Laegeforen; 2003 Sep; 123(18):2565-7. PubMed ID: 14714043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing therapy for inflammatory bowel disease.
    Robinson M
    Am J Gastroenterol; 1997 Dec; 92(12 Suppl):12S-17S. PubMed ID: 9395347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of mesalamine and nicotine in the treatment of inflammatory bowel disease.
    Bonapace CR; Mays DA
    Ann Pharmacother; 1997; 31(7-8):907-13. PubMed ID: 9220055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aminosalicylates for the treatment of inflammatory bowel disease.
    Leichtner AM
    J Pediatr Gastroenterol Nutr; 1995 Oct; 21(3):245-52. PubMed ID: 8523207
    [No Abstract]   [Full Text] [Related]  

  • 15. [Drug therapy of chronic inflammatory intestinal diseases].
    Raedler A; Reinecker C
    Immun Infekt; 1990 Aug; 18(4):121-6. PubMed ID: 2210794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Aminosalicylates and steroids in the treatment ot chronic inflammatory bowel diseases--consensus paper of the Working Group for Chronic Inflammatory Bowel Diseases of the OGGH].
    Dejaco C; Haas T; Kirchgatterer A; Miehsler W; Wenzl H; Knoflach P; Petritsch W; Vogelsang H; Reinisch W; Tilg H
    Z Gastroenterol; 2006 Jun; 44(6):525-38; discussion 539. PubMed ID: 16773519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.
    Clemett D; Markham A
    Drugs; 2000 Apr; 59(4):929-56. PubMed ID: 10804042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aminosalicylates.
    Campregher C; Gasche C
    Best Pract Res Clin Gastroenterol; 2011 Aug; 25(4-5):535-46. PubMed ID: 22122769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High thiopurine metabolite concentrations associated with lymphopenia in inflammatory bowel disease (IBD) pediatric patients receiving aminosalicylates combined with azathioprine.
    Nguyen TM; Le Gall C; Lachaux A; Boulieu R
    Int J Clin Pharmacol Ther; 2010 Apr; 48(4):275-81. PubMed ID: 20353749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New therapeutic possibilities in chronic inflammatory bowel diseases].
    Zeitz M
    Praxis (Bern 1994); 1997 Jun; 86(25-26):1071-4. PubMed ID: 9289806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.